Orion Pharma doses first patient in Phase 1/2 BICIDES trial of ODM-216 bispecific antibody in solid tumors

• Orion launched a Phase 1/2 trial of ODM-216 in advanced solid tumors, marking first human dosing for its first biologic program.
• Results have not been presented; the study will generate initial safety, drug-behavior, and early anti-tumor activity readouts for future disclosure.
• Program targets two immune checkpoints, expanding the company’s immuno-oncology pipeline beyond its historical focus on small-molecule drugs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orion Oyj published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050800OMX_____CNEWS_EN_GNW1001276294_en) on October 05, 2026, and is solely responsible for the information contained therein.